Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy with High-Dose IL-2 in Soft Tissue Sarcoma
NCT04052334Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Sep 2019
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC101 TIL + pembrolizumab in soft tissue sarcoma (STS), sponsored by Moffitt Cancer Center. Primary endpoint: Number of Participants Who Experienced Serious Adverse Events and Adverse Events at 12 months. Started Sep 2019; status: completed.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04052334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052334.